Freeline Therapeutics Holdings plc (FRLN)

Market Cap	28.91M
Revenue (ttm)	n/a
Net Income (ttm)	-100.67M
Shares Out	64.97M
EPS (ttm)	-2.12
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,457
Open	0.460
Previous Close	0.452
Day's Range	0.431 - 0.460
52-Week Range	0.390 - 1.280
Beta	0.51
Analysts	Buy
Price Target	5.10 (+1,033.33%)
Earnings Date	Apr 4, 2023

About FRLN

Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is verbrinacogene setparvovec (FLT180a), a gene therapy product candidate that is in Phase 1/2 clinical trials in adult males for the treatment of hemophilia B. The company's products also include FLT190, which is in Phase 1/2 clinical trial for the treatment of Fabry disease; and FLT201,...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Aug 7, 2020
• Employees: 235
• Stock Exchange: NASDAQ
• Ticker Symbol: FRLN

Analyst Forecast

According to 12 analysts, the average rating for FRLN stock is "Buy." The 12-month stock price forecast is $5.1, which is an increase of 1,033.33% from the latest price.

Price Target

$5.1

(1,033.33% upside)

Analyst Consensus: Buy